Abstract: Nanoparticle systems that genetically modify monocytes/macrophages in vivo to (1) recruit additional immune cells to a treatment site; (2) remain activated at the treatment site providing an on-going stimulatory signal to other immune cells; and (3) secrete bispecific immune-cell engaging antibodies that bind antigens on cells of interest at the treatment site and also bind and activate the recruited immune cells to destroy the bound cell. The systems can also inhibit the activity of transforming growth factor beta (TGF?).
Type:
Application
Filed:
December 31, 2020
Publication date:
October 19, 2023
Applicants:
Fred Hutchinson Cancer Center, Tidal Therapeutics, Inc.
Abstract: The present invention relates to a combination of sensors, a system and a method for monitoring incontinence and physiological parameters. The system includes a plurality of electrodes on an absorbent article including an absorbent core to be worn by a wearer being monitored, a device for electrical connection with the electrodes and for monitoring one or more electrical properties of the electrodes indicative of the occurrence of an incontinence event, an oxygen saturation sensor for monitoring the oxygen saturation of the blood of the wearer, and wherein the operation of the oxygen saturation sensor is controlled according to the body position of the wearer.
Abstract: A method and an installation facility for assembling a plurality of floating wind turbines (12). The method comprising establishing an installation facility by arranging an installation vessel (1), having a crane (4), at a sheltered place, mooring a barge (2) next to said vessel (1). Further transporting a plurality of turbine blades (6), a plurality of tower sections (8) and a plurality of nacelles (10) to said installation facility, lifting of these parts onto said installation facility. Further towing a first floating wind turbine foundation (11 a) to said installation facility, erecting a tower (8a) on said first foundation (11 a) by assembling a set of said tower sections (8), installing a nacelle (10) on top of said tower (8a), installing a set of turbine blades (6) onto said nacelle (10) to make a completed wind turbine (12a), and finally towing said first wind turbine (12a) away.
Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
October 17, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
Abstract: The current disclosure provides recombinant adenoviral vectors and adenoviral genomes that can accommodate or that contain a large transposon payload, for instance a transposon payload of up to 40 kb. The adenoviral vectors and genomes can deliver the large transposon payload into a target genome, for instance for gene therapy.
Type:
Application
Filed:
April 12, 2021
Publication date:
October 5, 2023
Applicants:
Fred Hutchinson Cancer Center, University of Washington
Inventors:
Andre Lieber, Hans-Peter Kiem, Hongjie Wang
Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.
Abstract: The present disclosure is based on the discovery that a clinical grade compound of Formula (I) potently blocks TGF-? activity and significantly reverse the activated phenotypes of myofibroblast in vitro. The compound of Formula (I) can be used in the treatment of fibrotic conditions in general, such as non-alcoholic steatohepatitis (NASH), cirrhosis, HBV infection, any liver disease, pulmonary fibrosis, interstitial lung disease, idiopathic pulmonary fibrosis (IPF), renal fibrosis, cardiac fibrosis, or any combination thereof.
Abstract: Humanized, chimeric, murine, and human antibody or antigen binding derivatives thereof that bind to an extracellular domain of interleukin-3 (IL-3) receptor ?-chain (CD123) anti-CD123 monoclonal antibodies are provided. Nucleic acids encoding the antibody or antigen binding derivative thereof that binds to an extracellular domain of interleukin-3 (IL-3) receptor ?-chain (CD123) and expression vectors comprising the nucleic acid are also provided. Bispecific affinity reagents comprising a first binding domain that specifically binds to an extracellular domain of interleukin-3 (IL-3) receptor ?-chain (CD123); and a second binding domain that specifically binds to a therapeutic payload and uses thereof are provided. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized, chimeric, or human anti-CD123 monoclonal antibodies; and cell lines that produce these monoclonal antibodies.
Type:
Application
Filed:
November 2, 2022
Publication date:
September 21, 2023
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Roland B. Walter, George S. Laszlo, Johnnie J. Orozco, Yukang Lin
Abstract: Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.
Abstract: In one aspect, the invention provides methods for determining the contributions of canid populations to a canid genome. The methods comprise the steps of: (a) obtaining the identity of one or both alleles in a test canid genome for each of a set of markers; and (b) determining the contributions of canid populations to the test canid genome by comparing the alleles in the test canid genome to a database comprising canid population profiles, wherein each canid population profile comprises genotype information for the set of markers in the canid populations.
Type:
Application
Filed:
December 8, 2022
Publication date:
September 7, 2023
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Elaine Ostrander, Leonid Kruglyak, Heidi G. Parker, Lisa V. Kim, Matthew Stephens, Tiffany B. Malek, Nathan B. Sutter, Scott Carlson
Abstract: The present disclosure describes methods of treating lymphoma that expresses a short histone H2A variant. In some embodiments, the method can comprise collecting a sample from a subject having or suspected of having lymphoma, detecting a short histone H2A variant (sH2A) expression level in the sample collected from the subject, and administering to the subject a therapeutically effective dose of an anthracycline agent, if the subject has sH2A variant expression level that is detectable. In other embodiments, the sH2A is the H2A.B variant. In other embodiments, the anthracycline agent can be aclarubicin.
Type:
Grant
Filed:
November 1, 2021
Date of Patent:
September 5, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Jay Francis Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew
Abstract: Compositions and methods to promote thymic function are described. The compositions and methods can activate the GPR39 receptor and/or a purinergic receptor, such as P2Y2. The activation can upregulate regenerative molecules, such as FOXN1, interleukin (IL)-22, IL-23, and bone morphogenetic protein 4 (BMP4).
Type:
Application
Filed:
November 3, 2021
Publication date:
August 24, 2023
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Jarrod Dudakov, Sinead Kinsella, Lorenzo Iovino
Abstract: Methods for treating malignancies including multiple myeloma (MM), methods for expanding immune cells, methods for characterizing and enhancing anti-tumor functions of immune cells, and methods for characterizing immune cell responses to agonist immunotherapies including decoy-resistant IL-18 (DR-18) therapies.
Abstract: A method for detecting the binding of a chromatin-associated factor of interest to a sequence of chromatin DNA in a cell, including: contacting a permeabilized cell or nucleus with a specific binding agent that specifically recognizes the chromatin-associated factor of interest, wherein the specific binding agent is linked to a nuclease that is inactive or an activatable transposome; activating the nuclease or transposase, thereby excising the sequence of chromatin DNA bound to the chromatin-associated factor of interest; isolating the excised DNA; and determining the sequence of the excised DNA, thereby detecting binding of a chromatin-associated factor of interest to a sequence of chromatin DNA in the cell.
Type:
Grant
Filed:
September 25, 2018
Date of Patent:
August 22, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Steven Henikoff, Hatice Seda Kaya Okur, Terri Dawn Bryson, Peter James Skene
Abstract: The present disclosure relates to immune cells that express an exogenous neoantigen and an immunogenicity enhancer, or to T cells that express an exogenous neoantigen, and their use in treating a disease or disorder, such as cancer for tumor associated neoantigens. Related expression constructs, kits, host cells, pharmaceutical compositions, and methods are also provided.
Abstract: The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.
Type:
Grant
Filed:
March 16, 2018
Date of Patent:
August 15, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Shannon K. Oda, Philip D. Greenberg, Thomas M. Schmitt
Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
Abstract: The invention relates to an incontinence monitoring system including a plurality of electrodes on an absorbent article including an absorbent core and a device for electrical connection with the electrodes and monitoring one or more electrical properties of the electrodes. A first set of the electrodes are adapted for detection of wetness associated with urinary incontinence events, and a second set of the electrodes are adapted for detection of faecal incontinence events. The invention also relates to an absorbent article, sensor and device as well as methods for monitoring incontinence.
Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
Type:
Grant
Filed:
February 19, 2020
Date of Patent:
August 8, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
August 8, 2023
Assignee:
Fred Hutchinson Cancer Center
Inventors:
J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan